MX368142B - Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab. - Google Patents

Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.

Info

Publication number
MX368142B
MX368142B MX2015015188A MX2015015188A MX368142B MX 368142 B MX368142 B MX 368142B MX 2015015188 A MX2015015188 A MX 2015015188A MX 2015015188 A MX2015015188 A MX 2015015188A MX 368142 B MX368142 B MX 368142B
Authority
MX
Mexico
Prior art keywords
ranibizumab
expression
preparation
purification method
novel cloning
Prior art date
Application number
MX2015015188A
Other languages
English (en)
Other versions
MX2015015188A (es
Inventor
Shandilya Harish
Gadgil Himanshu
Farkade Vivek
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of MX2015015188A publication Critical patent/MX2015015188A/es
Publication of MX368142B publication Critical patent/MX368142B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a la clonación, expresión y producción de Ranibizumab utilizando un abordaje novedoso para una proteína de mejor rendimiento y biológicamente activa.
MX2015015188A 2013-04-30 2014-04-28 Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab. MX368142B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1570MU2013 2013-04-30
PCT/IN2014/000274 WO2014178078A2 (en) 2013-04-30 2014-04-28 Novel cloning, expression & purification method for the preparation of ranibizumab

Publications (2)

Publication Number Publication Date
MX2015015188A MX2015015188A (es) 2016-09-07
MX368142B true MX368142B (es) 2019-09-20

Family

ID=51844062

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015188A MX368142B (es) 2013-04-30 2014-04-28 Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.

Country Status (7)

Country Link
US (1) US9914770B2 (es)
EP (1) EP2992021B1 (es)
CA (1) CA2911087A1 (es)
MX (1) MX368142B (es)
RU (1) RU2646098C2 (es)
WO (1) WO2014178078A2 (es)
ZA (1) ZA201508706B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2015287296A1 (en) * 2014-07-09 2017-02-02 Lupin Limited Dual cistronic bacterial expression system
HK1254752A1 (zh) * 2015-08-17 2019-07-26 Lupin Limited 用於抗体碎片的改进的复性方法
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
MX2019011343A (es) 2017-03-24 2019-11-18 Council Scient Ind Res Un procedimiento para la purificacion de fragmentos de anticuerpos recombinantes.
WO2018211529A1 (en) 2017-05-19 2018-11-22 Council Of Scientific & Industrial Research A method for producing refolded recombinant humanized ranibizumab
BR112020012336A2 (pt) 2017-12-19 2021-03-30 Akouos, Inc. Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
US12071476B2 (en) 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
CN112912104A (zh) 2018-08-17 2021-06-04 三钰生物科技股份有限公司 抗血管新生融合蛋白及其用途
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021072182A1 (en) * 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Methods for producing ranibizumab
US20240092883A1 (en) * 2019-10-11 2024-03-21 Coherus Biosciences, Inc. Methods of purifying ranibizumab or a ranibizumab variant
WO2021102173A1 (en) * 2019-11-21 2021-05-27 Unity Biotechnology Antibodies directed to tie-2 and methods of use
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
JP2024503784A (ja) * 2020-12-18 2024-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｎｐｒ１アゴニストに結合する免疫グロブリンタンパク質
CN115927472A (zh) * 2021-07-05 2023-04-07 武汉纽福斯生物科技有限公司 一种抗vegf抗体体内表达系统的构建和应用
EP4473011A1 (en) 2022-02-02 2024-12-11 Akouos, Inc. Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1100891A2 (en) * 1998-07-28 2001-05-23 California Institute Of Technology Expression of functional eukaryotic proteins
US6979556B2 (en) * 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
EP1385872A4 (en) 2001-05-11 2004-12-15 Res Dev Foundation NF-KAPPA B ACTIVATOR RECEPTOR INHIBITORS AND USES OF SUCH INHIBITORS
DE10238846A1 (de) * 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
AU2004230670B2 (en) * 2003-01-09 2010-11-25 Genentech, Inc. Purification of polypeptides
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
JP5010923B2 (ja) 2004-02-09 2012-08-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド アルブミン融合蛋白質
DK1748077T3 (da) 2004-04-20 2013-04-08 Ajinomoto Kk Fremgangsmåde til fremstilling af protein
WO2009021548A1 (en) * 2007-08-10 2009-02-19 Wacker Chemie Ag Expression of full length igg and secretion into the culture medium of prokaryotic cells
US20110003337A1 (en) * 2008-02-29 2011-01-06 Ramot At Tel-Aviv University Ltd. Immunoglobulin compositions and methods of producing same
US20090311750A1 (en) * 2008-06-13 2009-12-17 West James W Methods of converting fab sequences into single chain antibody sequences
AU2010221369B2 (en) * 2009-03-03 2014-03-13 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
BRPI1012321A8 (pt) * 2009-06-17 2016-09-27 Abbott Biotherapeutics Corp Anticorpos anti-vegf e seus usos
KR101753569B1 (ko) 2010-01-22 2017-07-04 베링거 인겔하임 인터내셔날 게엠베하 Ｆｃ―함유 단백질을 정제하는 크로마토그래피 방법
WO2011104307A2 (en) * 2010-02-25 2011-09-01 Graffinity Pharmaceuticals Gmbh Ligands for antibody purification by affinity chromatography
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification

Also Published As

Publication number Publication date
US9914770B2 (en) 2018-03-13
RU2646098C2 (ru) 2018-03-01
MX2015015188A (es) 2016-09-07
EP2992021A2 (en) 2016-03-09
EP2992021A4 (en) 2017-01-11
RU2015148746A (ru) 2017-06-05
US20160289314A1 (en) 2016-10-06
WO2014178078A3 (en) 2014-12-24
ZA201508706B (en) 2017-09-27
CA2911087A1 (en) 2014-11-06
WO2014178078A2 (en) 2014-11-06
EP2992021B1 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
MX2015015188A (es) Metodo de clonacion, expresion y purificacion novedoso para la preparacion de ranibizumab.
SG10201900948PA (en) Modified nucleotide linkers
PH12018501094A1 (en) Process for the preparation of an apoptosis-inducing agent
SA515361251B1 (ar) طريقة لزيادة تكوين حمض بيرو-جلوتاميك من بروتين
EA201790916A1 (ru) Новые лиганды rig-i и способы их получения
IN2014CH00247A (es)
IN2015KN00323A (es)
PH12017502240A1 (en) Recombinant microorganism for improved production of alanine
MY181068A (en) Recombinant microorganism for improved production of fine chemicals
IN2014CN03887A (es)
PH12016501094A1 (en) Recombinant microorganism for improved production of fine chemicals
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
IN2014MU00455A (es)
IN2013MU03070A (es)
IN2013CH04906A (es)
MY184085A (en) Method of protein manufacture
MY174840A (en) Microorganism producing o-acetyl-homoserine, and method for producing o-acetyl-homoserine by using same
MX2015010006A (es) Purificacion de proteinas mejorada a traves de una etapa de desglicosilacion.
MX349985B (es) Procedimiento de preparación de ésteres de fenilacetil aminoácido espirocíclicos con sustitución cis-alcoxi y derivados de 1h-pirrolidin-2,4-diona espirocicíclicos con sustitución cis-alcoxi.
MX368669B (es) Procedimiento para la preparación de 4-amino-1-((1s,4r,5s)-2-fluor o-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-o na.
HK1202555A1 (en) Process for the manufacture of cyclic undecapeptides
MX2015009565A (es) Proceso para elaborar derivados de magnolol.
EA201991474A1 (ru) Способы получения фитоина
MY173051A (en) Microorganism having producing ability of quinolinic acid and method for producing quinolinic acid using the microorganism
IN2013CH05865A (es)

Legal Events

Date Code Title Description
FG Grant or registration